[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.142.219. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
February 3, 1999

Coronary Events With Lipid-Lowering Therapy: The AFCAPS/TexCAPS Trial

Author Affiliations
 

Margaret A.WinkerMD, Deputy EditorIndividualAuthorPhil B.FontanarosaMD, Interim Co-EditorIndividualAuthor

JAMA. 1999;281(5):414-419. doi:10-1001/pubs.JAMA-ISSN-0098-7484-281-5-jbk0203

To the Editor: Although the authors of AFCAPS/TexCAPS1 are to be commended for including women in their study (the majority of the earlier studies included only men), too few women were included (15% [997/6605]) to allow them to find a statistically significant reduction in CHD events in women. Indeed, the difference in CHD events between lovastatin and women treated with placebo was not statistically significant (1.4% vs 2.6%).

First Page Preview View Large
First page PDF preview
First page PDF preview
×